{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:26:30Z","timestamp":1774992390818,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031715","name":"Ocular Therapeutix","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031715","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007816","name":"Alcon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007816","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtos.2025.11.010","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:11:58Z","timestamp":1764259918000},"page":"34-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Delphi panel on neuromodulation as a treatment strategy for dry eye disease: Unlocking the potential of natural tear production"],"prefix":"10.1016","volume":"39","author":[{"given":"Esen","family":"Akpek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyndon","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly K.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Nijm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Pflugfelder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esen","family":"Akpek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Fahmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjan","family":"Farid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaclyn","family":"Garlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyndon","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Karpecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecelia","family":"Koetting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Lighthizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Mah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomina","family":"Massaro-Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selena","family":"McGee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly K.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Nijm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Periman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Pflugfelder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Dr","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Starr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaci","family":"Theis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Wirta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2025.11.010_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exer.2013.10.008","article-title":"Complexity of the tear film: importance in homeostasis and dysfunction during disease","volume":"117","author":"Dartt","year":"2013","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jtos.2025.11.010_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exer.2020.108115","article-title":"Biological functions of tear film","volume":"197","author":"Pflugfelder","year":"2020","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jtos.2025.11.010_bib3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00003226-199811000-00002","article-title":"The pathology of dry eye: the interaction between the ocular surface and lacrimal glands","volume":"17","author":"Stern","year":"1998","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2025.11.010_bib4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2025.11.010_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ajo.2025.05.033","article-title":"TFOS DEWS III diagnostic methodology","volume":"279","author":"Wolffsohn","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2025.11.010_bib6","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1167\/iovs.16-19419","article-title":"Impact of dry eye disease on work productivity, and patients' satisfaction with over-the-counter dry eye treatments","volume":"57","author":"Nichols","year":"2016","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2025.11.010_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ajo.2019.01.026","article-title":"Estimated prevalence and incidence of dry eye disease based on coding analysis of a large, all-age United States health care system","volume":"202","author":"Dana","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2025.11.010_bib8","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3906\/sag-2002-143","article-title":"The negative effects of dry eye disease on quality of life and visual function","volume":"50","author":"Guo","year":"2020","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.jtos.2025.11.010_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ajo.2019.10.009","article-title":"Sustained gazing causes measurable decline in visual function of patients with dry eye","volume":"210","author":"Akpek","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2025.11.010_bib10","article-title":"Economic burden and loss of quality of life from dry eye disease in Canada","volume":"6","author":"Chan","year":"2021","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.jtos.2025.11.010_bib11","article-title":"TFOS DEWS III management and therapy report","volume":"0002\u20139394","author":"Jones","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2025.11.010_bib12","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2025.11.010_bib13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/ICO.0000000000003567","article-title":"Long-term safety and efficacy of a water-free cyclosporine 0.1% ophthalmic solution for treatment of dry eye disease: essence-2 ole","volume":"44","author":"Wirta","year":"2024","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2025.11.010_bib14","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1097\/ICO.0000000000003398","article-title":"Prospective assessment of loteprednol etabonate 0.25% for prevention of immunologic rejection after descemet membrane endothelial keratoplasty in eyes with fuchs dystrophy","volume":"43","author":"Price","year":"2024","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2025.11.010_bib15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial","volume":"26","author":"Leonardi","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2025.11.010_bib16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ophtha.2015.10.011","article-title":"Long-term natural history of dry eye disease from the patient's perspective","volume":"123","author":"Lienert","year":"2016","journal-title":"Ophthalmol Times"},{"key":"10.1016\/j.jtos.2025.11.010_bib17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40123-019-0188-4","article-title":"Evaluating patient experiences in dry eye disease through social media listening research","volume":"8","author":"Cook","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jtos.2025.11.010_bib18","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2147\/OPTH.S233194","article-title":"Treatment satisfaction among patients using anti-inflammatory topical medications for dry eye disease","author":"White","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2025.11.010_bib19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/ICO.0000000000003266","article-title":"Comparison of subjective responses to cyclosporine 0.05% versus lifitegrast 5.0% in individuals with dry eye disease","volume":"43","author":"Locatelli","year":"2024","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2025.11.010_bib20","series-title":"Poster presented at the ASCRS annual meeting","article-title":"Evaluation of treatment and switching patterns for dry eye disease medications using linked EHR and claims data","author":"Mbagwu","year":"2024"},{"key":"10.1016\/j.jtos.2025.11.010_bib21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40265-024-02016-5","article-title":"Perfluorohexyloctane ophthalmic solution: a review in dry eye disease","volume":"84","author":"Zhuang-Yan","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.jtos.2025.11.010_bib22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ophtha.2022.12.021","article-title":"NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study","volume":"130","author":"Tauber","year":"2023","journal-title":"Ophthalmol Times"},{"key":"10.1016\/j.jtos.2025.11.010_bib23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ajo.2023.03.008","article-title":"NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study","volume":"252","author":"Sheppard","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2025.11.010_bib24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jtos.2023.10.001","article-title":"Perfluorohexyloctane in dry eye disease: a systematic review of its efficacy and safety as a novel therapeutic agent","volume":"30","author":"Ballesteros-Sanchez","year":"2023","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2025.11.010_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2024.1452422","article-title":"Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials","volume":"4","author":"Fahmy","year":"2024","journal-title":"Front Ophthalmol"},{"key":"10.1016\/j.jtos.2025.11.010_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jtos.2018.11.002","article-title":"Neurostimulation in dry eye disease-past, present, and future","volume":"17","author":"Dieckmann","year":"2019","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2025.11.010_bib27","first-page":"2694","article-title":"In vivo confocal microscopy demonstrates intranasal neurostimulation-induced goblet cell alterations in patients with dry eye disease","volume":"58","author":"Dieckmann","year":"2017","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2025.11.010_bib28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jtos.2022.08.003","article-title":"A randomized, vehicle-controlled, phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1)","volume":"26","author":"Wirta","year":"2022","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2025.11.010_bib29","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1152\/jn.00657.2011","article-title":"Ocular dryness excites two classes of corneal afferent neurons implicated in basal tearing in rats: involvement of transient receptor potential channels","volume":"107","author":"Hirata","year":"2012","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.jtos.2025.11.010_bib30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jtos.2022.05.001","article-title":"Nicotinic acetylcholine receptor stimulation: a new approach for stimulating tear secretion in dry eye disease","volume":"25","author":"Pflugfelder","year":"2022","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2025.11.010_bib31","first-page":"2693","article-title":"Tear total lipid concentration in patients with dry eye following intranasal neurostimulation","volume":"58","author":"Green","year":"2017","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2025.11.010_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ajo.2017.03.002","article-title":"Randomized controlled crossover trial comparing the impact of sham or intranasal tear neurostimulation on conjunctival goblet cell degranulation","volume":"177","author":"Gumus","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2025.11.010_bib33","first-page":"2235","article-title":"Intranasal neurostimulator induces morphologial changes in meibomian glands in patients with dry eye disease","volume":"58","author":"Pondelis","year":"2017","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2025.11.010_bib34","first-page":"2673","article-title":"Effect of intranasal neurostimulation on tear protein content in patients with dry eye","volume":"58","author":"Woodward","year":"2017","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2025.11.010_bib35","first-page":"319","article-title":"The efficacy and safety of varenicline nasal spray for the management of dry eye signs: a systematic review and meta-analysis","volume":"23","author":"Bashrahil","year":"2023","journal-title":"Ophthalmol Times"},{"key":"10.1016\/j.jtos.2025.11.010_bib36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ophtha.2021.11.004","article-title":"Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3 randomized trial","volume":"129","author":"Wirta","year":"2022","journal-title":"Ophthalmol Times"},{"key":"10.1016\/j.jtos.2025.11.010_bib37","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/ICO.0000000000002941","article-title":"ONSET-1 phase 2b randomized trial to evaluate the safety and efficacy of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease","volume":"41","author":"Wirta","year":"2022","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2025.11.010_bib38","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0161-6420(80)35143-9","article-title":"Basic tear flow. Does it exist?","volume":"87","author":"Jordan","year":"1980","journal-title":"Ophthalmol Times"},{"key":"10.1016\/j.jtos.2025.11.010_bib39","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/00003226-199711000-00008","article-title":"Nasolacrimal stimulation of aqueous tear production","volume":"16","author":"Gupta","year":"1997","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2025.11.010_bib40","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1167\/iovs.09-5119","article-title":"Cold thermoreceptors, unexpected players in tear production and ocular dryness sensations","volume":"52","author":"Belmonte","year":"2011","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2025.11.010_bib41","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","article-title":"TFOS DEWS II pain and sensation report","volume":"15","author":"Belmonte","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2025.11.010_bib42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nature719","article-title":"Identification of a cold receptor reveals a general role for TRP channels in thermosensation","volume":"416","author":"McKemy","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jtos.2025.11.010_bib43","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0092-8674(02)00652-9","article-title":"A TRP channel that senses cold stimuli and menthol","volume":"108","author":"Peier","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.jtos.2025.11.010_bib44","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/nm.2264","article-title":"Ocular surface wetness is regulated by TRPM8-dependent cold thermoreceptors of the cornea","volume":"16","author":"Parra","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.jtos.2025.11.010_bib45","series-title":"Product monograph for alcoltremon 0.003%","year":"2025"},{"key":"10.1016\/j.jtos.2025.11.010_bib46","series-title":"Tear production associated with a novel TRPM8 agonist (AR-15512): results from phase 3 pivotal clinical studies (COMET-2 and COMET-3)","author":"Whitley","year":"2024"},{"key":"10.1016\/j.jtos.2025.11.010_bib47","series-title":"AR-15512: a novel TRPM8 agonist for the treatment of the signs and symptoms of dry eye: phase 3 pivotal study results","author":"Wirta","year":"2024"},{"key":"10.1016\/j.jtos.2025.11.010_bib48","article-title":"The Delphi method: an experimental study of group opinion","volume":"87","author":"Dalkey","year":"1969","journal-title":"Int J Med"},{"key":"10.1016\/j.jtos.2025.11.010_bib49","first-page":"1","article-title":"The Delphi technique: making sense of consensus","volume":"12","author":"Hsu","year":"2007","journal-title":"Practical Assess Res Eval"},{"key":"10.1016\/j.jtos.2025.11.010_bib50","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jtos.2025.11.010_bib51","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2147\/OPTH.S237832","article-title":"Physician satisfaction with anti-inflammatory topical medications for the treatment of dry eye disease","volume":"14","author":"White","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2025.11.010_bib52","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2147\/OPTH.S296510","article-title":"Real-world experience with lifitegrast ophthalmic solution (Xiidra((R))) in the US and Canada: Retrospective study of patient characteristics, treatment patterns, and clinical effectiveness in 600 patients with dry eye disease","volume":"15","author":"Hovanesian","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2025.11.010_bib53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/OPTH.S228838","article-title":"Managing dry eye disease and facilitating realistic patient expectations: a review and appraisal of current therapies","volume":"14","author":"Shen","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2025.11.010_bib54","first-page":"101","article-title":"A novel TRPM8 agonist relieves dry eye discomfort","volume":"17","author":"Yang","year":"2017","journal-title":"Ophthalmol Times"},{"key":"10.1016\/j.jtos.2025.11.010_bib55","series-title":"Presented at: the American academy of optometry annual meeting October 8-11. Boston, MA","article-title":"Acoltremon 0.003% leads to a statistically significant increase in tear volume and tear total lipid concentration: phase 3b study results","author":"Lighthizer","year":"2025"},{"key":"10.1016\/j.jtos.2025.11.010_bib56","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s40123-022-00530-x","article-title":"A single administration of OC-01 (varenicline solution) nasal spray induces short-term alterations in conjunctival goblet cells in patients with dry eye disease","volume":"11","author":"Dieckmann","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jtos.2025.11.010_bib57","series-title":"Handbook of research methods in health social sciences","article-title":"The Delphi technique","author":"Chalmers","year":"2019"},{"key":"10.1016\/j.jtos.2025.11.010_bib58","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/01.ico.0000214802.40313.fa","article-title":"Dysfunctional tear syndrome study group (2006). Dysfunctional tear syndrome: a Delphi approach to treatment recommendations","volume":"25","author":"Behrens","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2025.11.010_bib59","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bjophthalmol-2018-312581","article-title":"Classifying signs and symptoms of dry eye disease according to underlying mechanism via the Delphi method: the DIDACTIC study","volume":"103","author":"Labetoulle","year":"2019","journal-title":"Br J Ophthalmol"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012425001363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012425001363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:41:51Z","timestamp":1774989711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012425001363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":59,"alternative-id":["S1542012425001363"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2025.11.010","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delphi panel on neuromodulation as a treatment strategy for dry eye disease: Unlocking the potential of natural tear production","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2025.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}